Use of cyclosporine A in the treatment of refractory nephrotic syndrome in adults

Renal Failure

Volumn 18, Issue 5, 1996, Pages 775-784

  Meyrier, Alain ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PREDNISONE;

CONFERENCE PAPER; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; NEPHROTIC SYNDROME; OSTEOPOROSIS; PARESTHESIA; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT FAILURE; TREMOR;

EID: 0029861935     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229609047706     Document Type: Conference Paper

References (42)

1. Broyer M, Meyrier A, Niaudet P, Habib R: Minimal changes and focal segmental glomerulosclerosis. In Cameron S, Davison AM, Grünfeld JP, Kerr D, Ritz E (eds), Oxford Textbook of Clinical Nephrology. Oxford, Oxford University Press, 1992 pp 298-339.
2. Korbet S. Schwartz M, Lewis E: Primary focal segmental glomerulosclerosis; clinical course and response to therapy. Am J Kidney Dis 23:773-783, 1994.
3. Korbet SM: Management of idiopathic nephrosis in adults, including steroid-resistant nephrosis. Curr Opin Nephrol Hypertens 4:169-176, 1995.
4. Korbet SM, Schwartz MM, Lewis EJ: The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine 65:304-311, 1986.
5. Cameron JS: The nephrotic syndrome and its complications. Am J Kidney Dis 10:157-171, 1987.
6. Ponticelli C, Passerini P: Alkylating agents and purine analogues in primary glomerulonephritis with nephrotic syndrome. Nephrol Dial Transpl 6:381-388, 1991.
7. Meyrier A, Simon P: Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis. Adv Nephrol 17:127-150, 1988.
8. Meyrier A, Simon P, Perret G, Condamin-Meyrier MC: Remission of idiopathic nephrotic syndrome after treatment with cyclosporine A. Br Med J 292:789-792, 1986.
9. Tejani A, Butt K, Khawar R, et al: Cyclosporine (CYA) induced remission of relapsing nephrotic syndrome (RNS) in children. Proceeding of the 18th Annual Meeting of the American Society of Nephrol, 57A (abstract), 1985.
10. Meyrier A, Simon P, Perret G, Condamin MC: CsA in lipoid nephrosis and focal-segmental hyalinosis resistant to other treatments. Proceeding of the 18th Annual Meeting of the American Society of Nephrology, 48A (abstract), 1985.
11. Lagrue G, Laurent J, Belghiti D, Robeva R: Cyclosporine A and idiopathic nephrotic syndrome. Lancet 2:692-693, 1986.
12. Hoyer PF, Krull F, Brodehl J: CsA in frequently relapsing minimal-change nephrotic syndrome. Lancet 2:335, 1986.
13. Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar R: Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 33:729-734, 1988.
14. Verani RR, Hawkins EP: Recurrent focal segmental glomerulosclerosis: a pathological study of the early lesion. Am J Nephrol 6:263-270, 1986.
15. Brown CB, Cameron JS, Turner DR, et al: Focal segmental glomerulosclerosis with rapid decline in renal function ("malignant FSGS"). Clin Nephrol 10:51-61, 1978.
16. Melvin R, Bennett W: Management of nephrotic syndrome in childhood. Drugs 42:30-51, 1991.
17. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K: Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 17:687-692, 1991.
18. Shalhoub RJ: Pathogenesis of lipoid nephrosis: a disorder of T cell function. Lancet ii:556-559, 1974.
19. Tejani A, Ingulli E: Current concepts of pathogenesis of nephrotic syndrome. In Tejani A (ed), Cyclosporin in the Therapy of Renal Disease. Basel, Karger, 1995, pp 1-5.
20. Meyrier A: Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. In Tejani A (ed), Cyclosporin in the Therapy of Renal Disease. Basel, Karger, 1995, pp 28-48.
21. Niaudet P, Broyer M, Habib R: Serial renal biopsies in children with idiopathic nephrotic receiving cyclosporin. In Tejani A (ed), Cyclosporin in the Therapy of Renal Disease. Basel, Karger, 1995, pp 78-83.
22. Meyrier A, Niaudet P, Brodehl J: Optimal Use of Sandimmun in Nephrotic Syndrome. Berlin, Springer-Verlag, 1992, p 1.
23. Meyrier A, Noël LH, Auriche P, Callard P: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 45:1446-1456, 1994.
24. Savin VJ: Mechanisms of proteinuna in noninflammatory glomerular diseases. Am J Kidney Dis 21:347-362, 1993.
25. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M: A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453-460, 1991.
26. Meyrier A: Antiproteinuric and immunologic effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transpl 7:80-84, 1992.
27. Meyrier A: Treatment of glomerular disease with cyclosporine A. Nephrol Dial Transplant 4:923-931, 1989.
28. Zietse R, Wenting GJ, Kramer P, Schalekamp MADH, Weimar W: Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci 82:641-650, 1992.
29. Zietse R, Derkx FHM, Schalekamp MADH, Weimar W: Cyclosponn and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. In Tejani A (ed), Cyclosporin in the Therapy of Renal Disease. Basel, Karger, 1995, pp 6-18.
30. Ponticelli C, Rizzoni G, Edefonti A, et al: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43:1377-1384, 1993.
31. Feutren G, Mihatsch MJ: Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654-1660, 1992.
32. D'Agati VD: Morphologic features of cyclosporin nephrotoxicity. In Tejani A (ed), Cyclosporin in the Treatment of Renal Disease. Basel, Karger; 1995, pp 84-110.
33. Honkanen E, Törnroth T, Gronhagen-Riska C: Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transpl 7(Suppl 1):35-41, 1992.
34. Wakai S, Magil AB: Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 42:428-434, 1992.
35. Lee HS, Koh HI: Nature of progressive glomerulosclerosis in human membranous nephropathy. Clin Nephrol 39:7-16, 1993.
36. Ponticelli C, Zucchelli P, Passerini P, et al: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320:8-13, 1989.
37. Alexopoulos E, Sakellariou G, Memmos D, Karamitsos K, Leontsini M, Papadimitriou M: Cyclophosphamide provides no additional benefit to steroid therapy in the treatment of idiopathic membranous nephropathy. Am J Kidney Dis 21:497-503, 1993.
38. Imperiale TF, Goldfarb S, Berns JS: Are cytotoxic agents beneficial in idiopathic membranous nephropathy? a meta-analysis of the controlled trials. J Am Soc Nephrol 5:1553-1558, 1995.
39. Cattran DC: Use of cyclosporin in membranous and mesangioproliferative (IgA) nephropathy. In Tejani A (ed). Cyclosporin in the Therapy of Renal Disease. Basel, Karger, 1995, pp 49-58.
40. DeSanto NG, Capodicasa G, Giordano C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporine. Am J Nephrol 7:74-76, 1987.
41. Rostoker G, Belghiti D, Ben Maadi A, et al: Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63:335-341, 1993.
42. Cattran DC, Greenwood C, Ritchie S, et al: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47:1130-1135, 1995.